Drug research

Botensilimab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as AGEN1181

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183	AGEN	Phase 2	Completed	2026-01-05Actual
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044	AGEN	Phase 2	Active not recruiting	2027-09Estimated
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaNCT05529316	AGEN	Phase 2	Active not recruiting	2028-02Estimated

AGENCompletedPrimary completion: 2026-01-05 · Actual

Trial details

AGENActive not recruitingPrimary completion: 2027-09 · Estimated

Trial details

AGENActive not recruitingPrimary completion: 2028-02 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.